A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania

Abstract Background Understanding immunogenicity and safety of monovalent type 2 oral poliovirus vaccine (mOPV2) in inactivated poliovirus vaccine (IPV)–immunized children is of major importance in informing global policy to control circulating vaccine-derived poliovirus outbreaks. Methods In this open-label, phase 4 study (NCT02582255) in 100 IPV-vaccinated Lithuanian 1–5-year-olds, we measured humoral and intestinal type 2 polio neutralizing antibodies before and 28 days after 1 or 2 mOPV2 doses given 28 days apart and measured stool viral shedding after each dose. Parents recorded solicited adverse events (AEs) for 7 days after each dose and unsolicited AEs for 6 weeks after vaccination. Results After 1 mOPV2 challenge, the type 2 seroprotection rate increased from 98% to 100%. Approximately 28 days after mOPV2 challenge 34 of 68 children (50%; 95% confidence interval, 38%–62%) were shedding virus; 9 of 37 (24%; 12%–41%) were shedding 28 days after a second challenge. Before challenge, type 2 intestinal immunity was undetectable in IPV-primed children, but 28 of 87 (32%) had intestinal neutralizing titers ≥32 after 1 mOPV2 dose. No vaccine-related serious or severe AEs were reported. Conclusions High viral excretion after mOPV2 among exclusively IPV-vaccinated children was substantially lower after a subsequent dose, indicating induction of intestinal immunity against type 2 poliovirus.

[1]  O. Diop,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2020–June 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[2]  O. Diop,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  J. Weiner,et al.  Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden , 2019, BMJ Global Health.

[4]  John O. Konz,et al.  The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study , 2019, The Lancet.

[5]  J. Modlin,et al.  Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Wright,et al.  Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Grobbee,et al.  The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Pallansch,et al.  Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[9]  J. Weiner,et al.  Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine , 2018, The Journal of infectious diseases.

[10]  Lerato Seakamela,et al.  Diagnostic Assay Development for Poliovirus Eradication , 2017, Journal of Clinical Microbiology.

[11]  P. Wright,et al.  Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants , 2016, The Lancet. Infectious diseases.

[12]  N. Grassly,et al.  Unravelling mucosal immunity to poliovirus. , 2016, The Lancet. Infectious diseases.

[13]  L. Hampton,et al.  Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[14]  M. Pallansch,et al.  Standardized Methods for Detection of Poliovirus Antibodies. , 2016, Methods in molecular biology.

[15]  Walter A Orenstein,et al.  Polio vaccination: past, present and future. , 2015, Future microbiology.

[16]  M. Pallansch,et al.  Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. , 2014, The Journal of infectious diseases.

[17]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[18]  T. Wakita,et al.  Development of a Poliovirus Neutralization Test with Poliovirus Pseudovirus for Measurement of Neutralizing Antibody Titer in Human Serum , 2011, Clinical and Vaccine Immunology.

[19]  R. Sutter,et al.  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial , 2010, The Lancet.

[20]  A. Vincent,et al.  Rapid Group-, Serotype-, and Vaccine Strain-Specific Identification of Poliovirus Isolates by Real-Time Reverse Transcription-PCR Using Degenerate Primers and Probes Containing Deoxyinosine Residues , 2009, Journal of Clinical Microbiology.

[21]  David Heymann Global polio eradication initiative. , 2006, Bulletin of the World Health Organization.

[22]  R. Sutter,et al.  Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.